Feature: Novelos/FDA Meet Friday. DOW 11,000?
No ratings
Feature: Novelos/FDA Meet Friday. DOW 11,000? As we mentioned on November 8th, biotech Novelos (OTCBB: NVLT) meets with the FDA on December 2nd to discuss its impressive Phase 1/2 results for its NOV-002 treatment for non-small call lung cancer (NSCLC).